A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Bill: 117-s-4152
Sponsor: full_name: Sen. Kelly, Mark [D-AZ]
Introduced: 2022-05-05
Policy area: Health
Latest action: action_date: 2022-05-05
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2022-05-05
action_desc: Introduced in Senate
text: <p>This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.</p>

tv_txt: II 117th CONGRESS 2d Session S. 4152 IN THE SENATE OF THE UNITED STATES May 5, 2022 Mr. Kelly (for himself, Ms. Collins , and Ms. Sinema ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

1. Reauthorization of the Critical Path Public-Private Partnerships Section 566(f) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–5(f) ) is amended by striking $6,000,000 for each of fiscal years 2018 through 2022 and inserting $10,000,000 for each of fiscal years 2023 through 2027 .